-
Biotech Takes Innovative Approach To Raising Capital For Its Promising Anti-Cancer Drug
Monday, November 13, 2023 - 2:56pm | 206Read More...Dr. Vuong Trieu, CEO & Chairman of Oncotelic Therapeutics, Inc. was recently a guest on Benzinga’s All-Access. Oncotelic is a biotechnology company focused on developing RNA therapeutics for hard-to-treat cancers. The company has extensive experience in the field and its lead candidate OT...
-
Oncotelic Therapeutics' (OTCQB: OTLC) Lead Immunotherapy Candidate For Treating Deadly Cancers, OT-101, Could Hold Potential Applications In Multiple Multi-Billion Dollar Markets
Tuesday, October 10, 2023 - 8:12am | 842Read More...Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company. Its primary focus is on developing innovative drugs for oncology and infectious disease and aging. OT-101 is the company’s lead immuno-oncology drug candidate, showing promise in the treatment of deadly...
-
With Cancer Immunotherapy Market Set To Grow At Double-Digit CAGR Till 2032, This Company Plans To Ride The Wave Through Treatments For Complex Cancers
Monday, September 25, 2023 - 8:18am | 678Read More...Oncotelic Therapeutics Inc. (OTCQB: OTLC) is a clinical-stage biopharmaceutical company. Its primary focus is on developing innovative drugs for the treatment of orphan oncology indications, with an emphasis on rare and underserved cancer types including pancreatic cancer, glioma and glioblastoma....
-
The Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB:OTLC) Is Leading The Charge
Monday, September 11, 2023 - 8:47am | 808Read More...Solid tumors are abnormal clumps of cells that form in various tissues or organs of the body. Unlike liquid or cystic tumors, solid tumors do not contain any liquid components. They can occur in bones, muscles and organs, and can be either benign or malignant. Solid tumors can arise from different...
